Correlation between important genes of mTOR pathway (PI3K and KIT) in Iranian women with sporadic breast cancer

Maryam Rahimi1, Farkhondeh Behjati1, Nazanin Taheri1, Shadi Hosseini1, Hamid Reza Khorram Khorshid1, Fatemeh Aghakhani Moghaddam1, Masoud Karimlou2, Saghar Ghasemi1, Niloofar Bazazzadegan1, Fereidoon Sirati3, Elahe Keyhani*1

Received: 16 Jan 2018 Published: 31 Dec 2018

Abstract

Background: PI3K/Akt/mTOR pathway is a crucial pathway in the angiogenesis, tumor growth and cell differentiation of several cancers. The PI3K and KIT genes are key genes of this pathway. Previous studies have reported the importance of these genes in the development of gastrointestinal carcinoma, leukaemia, and melanomas. The role of mutations and overexpression of PI3K and KIT genes in breast cancer has been previously proved. This study investigates the correlation between PI3K and KIT gene mutations in sporadic breast cancer.

Methods: Multiplex Ligation-dependent Probe Amplification (MLPA) technique was used to determine the Copy Number Variation (CNV) of PI3K and KIT genes in 34 breast cancer tumours and PCR-sequencing was used to detect the mutation in PI3K exons 9 and 20.

Results: Our results reported that 27% of patients had CNV of the KIT gene; whereas, 20% and 17.5% of patients, had mutation and CNV in the PI3K gene, respectively. We did not found a significant correlation between the mutations of PI3K and KIT genes.

Conclusion: About two-tenth of the patients revealed CNV and lesser than two-tenth indicated mutation in the PI3K gene, whereas one-third of the patients demonstrated CNV in the KIT gene. Thus, administration of the PI3K and KIT gene inhibitor drugs might be proposed to suppress breast cancer in patients with mutation and CNV of each of these individual genes.

Keywords: mTOR pathway, PI3K gene, KIT gene, Breast Cancer

Introduction

The majority of genes that undergo mutation in human cancers play a direct role in the cell cycle, and most of them participate in signal transduction. PI3K/Akt/mTOR pathway forms one of the most crucial signal transduction pathways in cancer development (1). This pathway is crucial in the cell processes such as cell survival, growth, division, and angiogenesis. PI3K and KIT genes are essential to initiate this pathway, although these genes are active in other pathways (2, 3). For this reason, cancers such as breast cancer probably could be suppressed through inhibiting these genes. (4).

Previous studies have reported that mutations and overexpression of PI3KCA gene are essential in the ovarian, endometrial, thyroid, nasopharyngeal and colorectal cancers (5-8).
Alternatively, several studies have reported that mutations and overexpression of KIT gene can develop malignancies such as gastrointestinal carcinoma, leukaemia, and melanomas (9-14).

The Copy Number Variation (CNV) of PIK3CA and KIT genes accelerate cancer development and determines the prognosis and sensitivity to the anticancer drugs (15-16).

Oncogenic mutations, in particular, exons 9 and 20, and increased CNV in the PI3K pathway generally activate the phosphatidylinositol-4, 5-bisphosphate 3-kinase-catalytic subunit alpha (PIK3CA) mutation, which has been identified in several breast cancer subtypes. PIK3CA exons 9 and 20 are coding p110α domains and tyrosine kinase domain respectively. The G>A mutation in E542K and A>G mutation in H1047R are common mutations in exons 9 and 20 (2, 17, 18).

Furthermore, KIT genes is a kind of receptor tyrosine kinase performing in cell signal transduction. The stem cell factor (SCF) is bound to KIT and activated it. Phosphorylation cascade activation is followed by activation of various transcription factors (3). CNV and overexpression of the KIT gene are crucial in developing breast malignant tumours (19).

Further research is required to study the suppression of the malignant tumours such as breast cancer by using drugs which inhibit PI3K and KIT genes such as imatinib and sunitinib. In this study, we investigated the CNV of KIT and PIK3CA genes, mutation of PIK3CA exons 9 and 20, and the relation between them in sporadic breast cancer.

**Methods**

**Patients**

50 tissue samples of breast cancer were selected with the following criteria: female, primary, sporadic, no history of treatment regardless of age or histopathological sub-type from Mehrad Hospital (Tehran, Iran). All samples were collected from the tumour regions and DNA was extracted from them. The quality and quantity of DNAs were assessed by agarose gel electrophoresis and NanoDrop ND 2000 spectrophotometer. They were amplified by the PCR technique for 50 tissue samples of breast cancer using SALSA P354-A2 and P173-A2 kits. DNA was amplified by the PCR technique for 50 samples followed by mutation analysis by direct DNA sequencing. The sequencing results were analysed using codon code aligner and Gene Runner software.

**Statistical analysis**

Data were analysed using SPSS 19.0 statistical package. Fisher’s exact tests were used to analyse the association between the increase in copy number and mutations of PI3K gene, and CNV of KIT. A p-value less than 0.05 was considered as statistically significant.

**Results**

**MLPA**

We used these kits to investigate CNV of the KIT gene and exons 2, 7 and 19 of the PI3K gene. Briefly, the DNA extracted from the dissected tumours and normal control samples were pre-heated to 98°C, and then the salt solution and probe mix were added to the DNA. After the ligation of annealed nucleotides, the target genes were amplified using polymerase chain reaction (PCR). PCR products were separated on an ABI3730-XL capillary sequencer (Applied Biosystems, Foster City, CA, USA). PI3K and KIT copy numbers were analysed using Coffalyser (ver. 140721.1958). The cut-off values between 0.7 and 1.3 were considered normal. Results below 0.7 or between 1.3 and 2 were interpreted as deletion and low-level amplification of gene, respectively; and values over 2 were referred to as high-level amplification.

**PCR-Sequencing**

Primers for exons 9 and 20 of PI3K gene were designed by primer 3 and UCSC genome browser (CinnaGen-Iran). Self-dimers, heterodimers and the melting temperature of the primers were checked by OligoAnalyzer (Table 1). DNA was amplified by the PCR technique for 50 samples followed by mutation analysis by direct DNA sequencing. The sequencing results were analysed using codon code aligner and Gene Runner software.

**Table 1.** Primer Sequences of 9 and 20 exons

| Exon | Sequence(5'→3') | Product Size | Annealing temperature |
|------|----------------|--------------|-----------------------|
| 9    | Forward: GGCCTAATTCGGAGTTCATCATTCTGTCGCCGACG <br> Reverse: GAAAAAGCATTTAATGCTGCACTACC | 616 | 58 |
| 20   | Forward: TCATTGTGCTTCAAATCCTGACC <br> Reverse: GGTCTTTGCTGCTGAGAGT | 388 | 60 |

**PCR-Sequencing**

Primers for exons 9 and 20 of PI3K gene were designed by primer 3 and UCSC genome browser (CinnaGen-Iran). Self-dimers, heterodimers and the melting temperature of the primers were checked by OligoAnalyzer (Table 1). DNA was amplified by the PCR technique for 50 samples followed by mutation analysis by direct DNA sequencing. The sequencing results were analysed using codon code aligner and Gene Runner software.

**Statistical analysis**

Data were analysed using SPSS 19.0 statistical package. Fisher’s exact tests were used to analyse the association between the increase in copy number and mutations of PI3K gene, and CNV of KIT. A p-value less than 0.05 was considered as statistically significant.

**Results**

**MLPA**

MLPA analysis was performed successfully in all tumour samples using SALSA P354-A2 and P173-A2 kits. The increasing copy number of PI3K gene was observed in 4 of the 40 patients, whereas that of the KIT gene was observed in 12 of the 44 patients.

**PCR-Sequencing**

Mutation in exons 9 and 20 of PI3K gene was detected in 20% of the patients. Two patients showed G>A mutation in E542K and nine with A>G mutation in H1047R (Table 2 and Fig. 1). Other cases were normal.

The present study indicates that the increase in copy number and hot spot mutations in PI3K gene are not significantly correlated with an increase in the copy number of the KIT gene (Table 3).
Discussion

This is the first study in Iranian population which focused on the relationship between PI3K and KIT genes for PI3K/Akt/mTOR pathway. Although KIT and PI3K genes are activated and participate in several common pathways, we did not observe any significant correlation between them; one of the possible reasons might be the activation of the PI3K and KIT genes separately by other pathways and genes.

In this study, two-tenth of the patients reported mutations in exons 9 and 20, lesser than two-tenth patients revealed an increased copy number in the PI3K gene. PI3K gene could be crucial in cancer development, with an increased risk of developing breast cancer. Administering tyrosine kinase inhibitor drugs could suppress breast cancer.

In previous studies, the expression level of this gene and CNV was different. This can be related to the genetic diversity of the population (18, 20).

Our investigation, like other studies, showed mutations of G>A in E542K and A>G in H1047R are the most prevalent mutations in PI3K gene in patients with sporadic breast cancer.

Table 2. The results of sequencing of 9 and 20 exons of PI3K gene

| Case | Mutation | Nucleotide change |
|------|----------|------------------|
| 1    | H1047R c:3140 | A>G              |
| 2    | H1047R c:3140 | A>G              |
| 3    | E542K c:1624  | G>A              |
| 4    | E542K c:1624  | G>A              |
| 5    | H1047R c:3140 | A>G              |
| 6    | H1047R c:3140 | A>G              |
| 7    | H1047R c:3140 | A>G              |
| 8    | H1047R c:3140 | A>G              |
| 9    | H1047R c:3140 | A>G              |
| 10   | H1047R c:3140 | A>G              |
| 11   | H1047R c:3140 | A>G              |

Table 3. Comparisons between CNV of KIT, PI3K, and 9 and 20 exons of PI3K gene

|      | KIT    | PI3k-CNv | PI3K-9 and 20 exons |
|------|--------|----------|---------------------|
| KIT  | Pearson Correlation | 0.069 | 0.656               |
| p-value | 0.547 | 0.145     |
| N     | 34     | 39        |

PI3K-CNv Pearson Correlation 0.069 0.238
p-value 0.656 0.145
N 44 39

PI3K-9 and 20 exons Pearson Correlation 0.069 0.238
p-value 0.656 0.145
N 44 39

Similar to our study, other studies such as findings of Ian J. Majewski, reported that 23% patients with breast cancer had a mutation in the PI3K gene or the study of SibylleLoibl that 21.4% patients had a mutation in this gene (2, 22). Alternatively, we confirmed results of Irina Palimarul and Mohammad Firoozinia (18, 23).

Our findings revealed that almost one-third of the patients have increased copy number in KIT; we investigated CNV of KIT gene using MLPA (P354-A2 kit, personal communication with MRC Holland). This kit was initially designed and routinely used for piebaldism disease. Since the KIT gene is crucial in the key pathways such as angiogenesis, tumour growth and cell differentiation, we used it to investigate the CNV of KIT gene in patients with sporadic breast cancer. We confirmed the results of previous studies that have reported maximum mutation of the KIT gene in breast cancer, unlike other cancers, is an increase in CNV.

In most cases, increase in CNV could be lead to gene overexpression.

Alternatively, in correlation to other studies, reported overexpression of the KIT gene as a crucial factor in de-
mTOR pathway and breast cancer

veloping breast cancer, and no correlation between an increase in the copy number and overexpression of the KIT gene (19, 24-29).

We presume that other mechanisms are also involved. These include epigenetic variation and translational, post-transcriptional and protein degradation regulations causing gene overexpression without altering these genes; however, the small sample size could also contribute to this discordance.

In the present study, KIT and PI3K genes revealed an increase in the copy number in sporadic breast cancer. Alternatively, several genes that can change the structure and function of a protein are essential for administering tyrosine kinase inhibitor drugs, in particular for gastrointestinal tumours, as they are resistant to these drugs (30). Therefore, although no significant correlation between these genes was established, each gene on its own can probably be used for targeted therapy with tyrosine kinase inhibitors.

Tyrosine kinase inhibitors are essential drugs, which have been successfully administered in cancers such as gastrointestinal cancer and leukaemia (31, 32); however, further studies are warranted to verify these initial findings.

Conclusion

CNV of PI3K gene was seen in 20% of 34 cases with sporadic breast cancer, while mutation in the same gene in less than 20%. In 30% of cases CNV of KIT gene was evident and no correlation was detected between PI3K and KIT CNVs. Since these are two important genes in development cancer, maybe one or both could be used as target in tyrosine kinase inhibitor drugs in sporadic breast cancer.

Conflict of interest

All authors declare that they have no conflict of interests.

References

1. Sever R, Brugge S. Signal Transduction in Cancer. Cold Spring Harbor Laboratory Press. 2017;5(4):a060698.
2. Okkenhaug K. Signaling by the phosphoinositide 3-kinase family in immune cells. Annu Rev Immunol. 2013;31:675-704.
3. Miettinen M, Lasota J. KIT (CD117): A Review on Expression in Normal and Neoplastic Tissues, and Mutations and Their Clinicopathologic Correlation. Appl Immunohistochem Mol Morphol. 2005; 13:205–220.
4. Shimizu K, Oka N. Cancer anti-angiogenic therapy. Biol Pharm Bull. 2004;27:599-605.
5. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, et al. PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (HER2) therapy in primary HER2-overexpressing breast cancer. J Clin Oncol. 2014;32(29):3212-3220.
6. Majewski IJ, Nuciforo P, Mitteregger L, Bosma AJ, Eidtmann H, Fe可爱 and Neoplastic Tissues, and Mutations and Their Clinicopathologic Correlation. Appl Immunohistochem Mol Morphol. 2004;27:599-605.
7. Or YYY, Hui ABU, To KF, Lam CNY, Lo KU. PIK3CA mutations in gastrointestinal carcinoma. Int J Cancer. 2006; 118(4):1065-1067.
8. Garcia-Rostán G1, Costa AM, Pereira-Castro I, Salvatore G, Hernandez R, Hermesm MJ, Herrero A, et al. Mutation of the PIK3CA gene in anaplastic thyroid cancer. Cancer Res. 2005;65(22):10199-10207.
9. Tuveson D, Willis N, Jacks T, Giri J, Singer S. ST5171 inactivation of the gastrointestinal stromal tumor c-KIToncoprotein: biological and clinical implications. Oncogene. 2001;20:5054-58.
10. Orsenigo M, Birch S, Riva C, Conca E, Bertulli R, Dileo P, et al. Fluorescence in situ hybridization analysis and immunophenotyping of c-Kit/PDGFRα and Bel-2 expression in gastrointestinal stromal tumors. Anal Quant Cytobiolst. 2010;32(4):225-33.
11. Antonescu C, Romeo S, Zhang L, Nade K, Hochberg J, Nielsen G, et al. Amplification in Gastrointestinal Stromal Tumor to an Anaplastic KIT Negative Phenotype – a Diagnostic Pitfall. Morphologic and Molecular Characterization of 8 Cases Occurring either de-novo or after Imatinib Therapy. Am J Surg Pathol. 2013;37(3):385-392.
12. Malaise M, Steinbach D, Corbacho S. Clinical implications of c-Kit mutations in acute myelogenous leukemia. Find out how to access preview-only content. Curr Hematol Malignant Reports. 2009;4(2): 77-82.
13. Renneville A, Roumier C, Biggio V, Nobourel O, Boissel N, Fenaux P, et al. Cooperating gene mutations in acute myeloid leukemia: a review of the literature. Leukemia. 2008;22:915-951.
14. Beadling C, Jacobson-Dunlop E, Hodi FS, Le C, Warrick A, Patterson J, et al. KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res. 2008;14(42):6821-8.
15. Hirsch FR, Varella-Garcia M, Bunn PA Jr, Di Maria MV, Veeve R, Brennes RM, et al. Epidermal growth factor receptor in nonsmall-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol. 2003; 21(6):3798-807.
16. Heinrich MC, Blanke CD, Druker BJ, Corless CL. Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol. 2002;20:1692-1703. 17. Arsenic R, Lehnmann A, Budeczies J, Koch I, Prinzler J, Kleine-Tebbe A, et al. Analysis of PIK3CA mutations in breast cancer subtypes. Appl Immunohistochem Mole Morphol. 2014;22(1):50-56.
18. Firoozinia M, Zareian Jahromi M, Zoroofchian Moghadamtauosi S, Nikzad S, Abdul Kadar H. PIK3CA gene amplification and PIK3C alpha-110 protein expression in breast carcinoma. Int J Med Sci. 2014; 11(6):620.
19. Liu J, Liu X, Feng X, Liu J, Li S, Zhang W, et al. C-kit overexpression correlates with KIT gene copy numbers increases in phyllodes tumors of the breast. Breast Cancer Res Treat. 2014;149(2):395-401.
20. Gonzalez-Angulo AM, Chen H, Karuturi MS, Chavez-MacGregor M, Tsavachidis S, Meric-Bernstern F. Frequency of mesenchymal-epithelial transition factor gene (MET) and the catalytic subunit of phosphoinositide-3-kinase (PI3KCA) copy number elevation and correlation with outcome in patients with early-stage breast cancer. Cancer. 2013;119(1):7-15.
21. Loibl S, Minckwitz G, Schneeweiss A, Paepke S, Lehnmann A, Rezaei M, et al. PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (HER2) therapy in primary HER2-overexpressing breast cancer. J Clin Oncol. 2014;32(29):3212-3220.
22. Majewski I, Ueicoforo P, Mitteregger L, Bosma AJ, Eidtmann H, Holmes E, et al. PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2–targeted therapies in breast cancer. J Clin Oncol. 2015;33;12(12):1334-1339.
23. Palmarini I, Brüggmann A, Wium-Andersen MK, Nexo E, Sorensen BS. Expression of PIK3CA, PTEN mRNA and PIK3CA mutations in primary breast cancer: association with lymph node metastases. Springerplus. 2013;2(1):464.
24. Lee JY, Park K, Lim SH, Kim HS, Yoo KH. Mutational profiling of brain metastasis from breast cancer: matched pair analysis of targeted sequencing between brain metastasis and primary breast cancer. Oncotarget. 2015;6(41):43731-42.
25. Gilbert JA, Goetz MP, Reynolds CA, Ingle JN, Giordano FK. Molecular analysis of metastatic breast carcinoma high EGFR copy number via aminosy. Mol Cancer Ther. 2008;7(4):944-951.
26. Kondo-Pafiti A, Arkadopoulos N, Gennatas C, Michalaki V, Frangou-Phelegmonous M. Expression of c-kit in common benign and malignant breast lesions. Tumori. 2010;96(6):978-984.
27. Johansson I, Aaltonen EK, Ebbesson D, Grabau D, Wigerup C, Bernström-Forsberg A. KIT gene copy number elevation and correlation with outcome in patients with early-stage breast cancer. Cancer Res. 2005;65(22):10199-10207.
28. Tuveson D, Willis N, Jacks T, Giri J, Singer S. ST5171 inactivation of the gastrointestinal stromal tumor c-KIToncoprotein: biological and clinical implications. Oncogene. 2001;20:5054-58.
29. Zhu Y, Wang Y, Guan B, Rao Q, Wang J, Ma H, et al. C-kit and PDGFRA gene mutations in triple negative breast cancer. Int J Clin Exp Pathol. 2014;7(7):4280-4285.

30. Antonescu C, Romeo S, Zhang L, Nafa K, Hornick J, Nielsen G, et al. Dedifferentiation in Gastrointestinal Stromal Tumor to an Anaplastic KIT Negative Phenotype – a Diagnostic Pitfall. Morphologic and Molecular Characterization of 8 Cases Occurring either de-novo or after Imatinib Therapy. Am J Surg Pathol. 2013; 37(3):385–392.

31. Poveda A, García del Muro X, López Guerrero J, Martínez V, Romero I, Valverde C, et al. GEIS 2013 guidelines for gastrointestinal sarcomas (GIST). Cancer Chemother Pharmacol. 2014;74:883–898.

32. Heinrich MC, Blanke CD, Druker BJ, Corless CL. Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol. 2002;20:1692–1703.